The Jewel P-WCD detects and treats life-threatening ventricular tachycardia and ventricular fibrillation, and is designed to promote compliance and fit into a patient’s daily life.

Providers:

Login to the clinical portal to access important information about the Jewel.

LOGIN

The Jewel P-WCD detects and treats life-threatening ventricular tachycardia and ventricular fibrillation, and is designed to promote compliance and fit into a patient’s daily life.

Providers:

Login to the clinical portal to access important information about the Jewel.

LOGIN

The Jewel Purpose and Overview

The Jewel continuously monitors a patient’s heart activity, detects ventricular tachycardia and ventricular fibrillation, and automatically delivers an electrical shock to restore normal heart rhythms.

You have prescribed the Jewel to your patient for a temporary period so that they are protected from specific life-threatening heart rhythms 24 hours a day, 7 days a week. The Jewel is not an implanted device. It is a device that is externally worn on the patient’s skin.

Clinical Trial Description

The Jewel IDE Study

A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest.

Objective

To demonstrate the safety and clinical effectiveness of the Jewel P-WCD.

Principal Investigators

John Hummel, MD

The Ohio State University

  • Director, Electrophysiology Section
  • Professor of Cardiovascular Medicine
  • Over 150 Publications in Cardiac Electrophysiology

Javed Butler, MD

University of Mississippi

  • Patrick H. Lehan Chair in Cardiovascular Research

  • Chairman and Professor, Department of Medicine

  • Over 650 Peer-reviewed Publications

  • Member of Editorial Boards of Several Peer-reviewed Cardiovascular Journals

Roxana Mehran, MD

Mount Sinai

  • Director of Interventional Cardiovascular Research and Clinical Trials

  • Chief Scientific Officer, Clinical Trials Center, Cardiovascular Research Foundation

  • Member, Board of Trustees, Society of Cardiac Angiography and Interventions

SCIENTIFIC ADVISORS

Bob Harrington, MD

Chair of Stanford University

  • Interventional Cardiologist
  • Professor of Medicine and Chairman of the Department of Medicine at Stanford University
  • Former Director of the Duke Clinical Research Institute (DCRI)
  • Author of more than 500 Articles and Edited Five Textbooks
  • Member and Chair of US FDA Cardiovascular and Renal Drugs Advisory Committee

Harlan Krumholz, MD

Director of Yale Center for Outcomes Research and Evaluation

  • Cardiologist
  • Professor Yale School of Medicine
  • Global Thought Leader on Outcomes Based Research
  • Author of more than 800 Articles and Two Books
  • Board of Trustees ACC

This product is not currently available for sale in the U.S.